JP6463130B2 - 腫瘍転移及び腫瘍形成の予防及び治療のための化合物並びに方法 - Google Patents

腫瘍転移及び腫瘍形成の予防及び治療のための化合物並びに方法 Download PDF

Info

Publication number
JP6463130B2
JP6463130B2 JP2014547550A JP2014547550A JP6463130B2 JP 6463130 B2 JP6463130 B2 JP 6463130B2 JP 2014547550 A JP2014547550 A JP 2014547550A JP 2014547550 A JP2014547550 A JP 2014547550A JP 6463130 B2 JP6463130 B2 JP 6463130B2
Authority
JP
Japan
Prior art keywords
cancer
compound
phenyl
group
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014547550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502367A (ja
JP2015502367A5 (enExample
Inventor
フランコウスキー、ケヴィン
パトナイク、サマルジット
フアン、スイ
ホセ マルガン、フアン
ホセ マルガン、フアン
ノートン、ジョン
ジェイ． シェーネン、フランク
ジェイ． シェーネン、フランク
サウソール、ノエル
ティトゥス、スティーヴン
チェン、ウェイ
ワン、チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas
Original Assignee
University of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas filed Critical University of Kansas
Publication of JP2015502367A publication Critical patent/JP2015502367A/ja
Publication of JP2015502367A5 publication Critical patent/JP2015502367A5/ja
Application granted granted Critical
Publication of JP6463130B2 publication Critical patent/JP6463130B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2014547550A 2011-12-16 2012-12-17 腫瘍転移及び腫瘍形成の予防及び治療のための化合物並びに方法 Active JP6463130B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161576780P 2011-12-16 2011-12-16
US61/576,780 2011-12-16
PCT/US2012/070155 WO2013090912A1 (en) 2011-12-16 2012-12-17 Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017102107A Division JP6726640B2 (ja) 2011-12-16 2017-05-23 腫瘍転移及び腫瘍形成の予防及び治療のための化合物並びに方法

Publications (3)

Publication Number Publication Date
JP2015502367A JP2015502367A (ja) 2015-01-22
JP2015502367A5 JP2015502367A5 (enExample) 2016-02-25
JP6463130B2 true JP6463130B2 (ja) 2019-01-30

Family

ID=47436279

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014547550A Active JP6463130B2 (ja) 2011-12-16 2012-12-17 腫瘍転移及び腫瘍形成の予防及び治療のための化合物並びに方法
JP2017102107A Active JP6726640B2 (ja) 2011-12-16 2017-05-23 腫瘍転移及び腫瘍形成の予防及び治療のための化合物並びに方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017102107A Active JP6726640B2 (ja) 2011-12-16 2017-05-23 腫瘍転移及び腫瘍形成の予防及び治療のための化合物並びに方法

Country Status (7)

Country Link
US (2) US9663521B2 (enExample)
EP (1) EP2791142B1 (enExample)
JP (2) JP6463130B2 (enExample)
AU (2) AU2012353651B2 (enExample)
CA (1) CA2859370C (enExample)
ES (1) ES2748590T3 (enExample)
WO (1) WO2013090912A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2791142B1 (en) * 2011-12-16 2019-07-03 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis
MY194204A (en) * 2014-08-04 2022-11-21 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US9877966B1 (en) * 2015-08-10 2018-01-30 Eugene J. Oliva Combination therapy for the inhibition of metastasis and tumorigenesis
US11241436B2 (en) * 2017-01-25 2022-02-08 Northwestern University Autophagy inducers for treatment of CNS conditions
US20210186972A1 (en) * 2018-05-15 2021-06-24 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis
JP2021098692A (ja) 2019-12-20 2021-07-01 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ 核内受容体に対して活性の化合物
PE20230240A1 (es) 2019-12-20 2023-02-07 Nuevolution As Compuestos activos frente a receptores nucleares
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
WO2024026064A1 (en) * 2022-07-29 2024-02-01 The University Of North Carolina At Chapel Hill Enhancing antimetastasis activity using targeted protein degradation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US20030114467A1 (en) 2001-06-21 2003-06-19 Shakespeare William C. Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
WO2009042294A2 (en) * 2007-08-10 2009-04-02 Burnham Institute For Medical Research Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AU2010307262A1 (en) * 2009-07-10 2012-03-01 Microbiotix, Inc. Inhibitors of filovirus entry into host cells
EP2791142B1 (en) * 2011-12-16 2019-07-03 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis
JP6681070B2 (ja) * 2015-11-19 2020-04-15 国立大学法人 岡山大学 光ファイバ装置及びセンサシステム

Also Published As

Publication number Publication date
CA2859370C (en) 2021-01-26
WO2013090912A1 (en) 2013-06-20
US20170260192A1 (en) 2017-09-14
ES2748590T3 (es) 2020-03-17
JP2017200921A (ja) 2017-11-09
JP2015502367A (ja) 2015-01-22
AU2012353651A1 (en) 2014-07-10
AU2017276258A1 (en) 2018-01-18
US9663521B2 (en) 2017-05-30
CA2859370A1 (en) 2013-06-20
US10301314B2 (en) 2019-05-28
EP2791142B1 (en) 2019-07-03
AU2012353651B2 (en) 2017-09-14
JP6726640B2 (ja) 2020-07-22
EP2791142A1 (en) 2014-10-22
AU2017276258B2 (en) 2019-10-03
US20140323438A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
JP6463130B2 (ja) 腫瘍転移及び腫瘍形成の予防及び治療のための化合物並びに方法
US20240294487A1 (en) Inhibitors of the ire-1/xbp-1 pathway and methods of using thereof
CN112225724B (zh) 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
JP6815318B2 (ja) 二官能性分子によって標的化タンパク質分解を誘導する方法
WO2014105952A2 (en) Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
AU2014240003B2 (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
JP2018513191A (ja) Ｂａｃｅ１阻害剤としての化合物およびそれらの使用
US20240182429A1 (en) Heterocyclic compound as tyk2 pseudokinase domain inhibitor, synthetic method, and use
EA020609B1 (ru) ИМИДАЗО[1,2-а]ПИРИДИН-2-ИЛФЕНИЛ ПРОИЗВОДНЫЕ ДЛЯ ЛЕЧЕНИЯ РАКА
EP3099679A1 (en) Itraconazole analogues and methods of use thereof
US20210179577A1 (en) Aromatic sulfonamide derivatives for the treatment of ischemic stroke
WO2013055793A1 (en) Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
TWI828289B (zh) 作為tyk2/jak1假激酶結構域抑制劑的化合物及合成和使用方法
JP2021527692A (ja) Ｏａｔ３の阻害剤を用いた神経変性に関連する状態の処置方法
US9877966B1 (en) Combination therapy for the inhibition of metastasis and tumorigenesis
AU2013328979A1 (en) Compounds for treating Rac-GTPase mediated disorder
US9656984B2 (en) PI3K/AKT/mTOR inhibitors and pharmaceutical uses thereof
US20240140947A1 (en) Compound for the treatment of cancer
WO2016204988A1 (en) Autophagy modulators for treating neurodegenerative diseases
TW202327576A (zh) 吡咯烷類化合物的鹽、晶型及其製備方法
US20200347044A1 (en) Compounds for Treating Rac-GTPase Mediated Disorder

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20141009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160104

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170523

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170530

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180305

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181228

R150 Certificate of patent or registration of utility model

Ref document number: 6463130

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250